Allt inom Corporate Information

Comments on news about the license on a long-acting technology platform published this Monday

Ascendis Pharma, a prodrug technology platform company announced yesterday that they have signed a license agreement with Novo Nordisk. “Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases”. “A once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate”.

Nanexa presented NEX-22 at PODD in Boston

Nanexa’s presentation of NEX-22 was received with great interest at the global conference PODD in Boston.